|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
Verve Therapeutics, Inc. (VERV) |
|
|
$0.00 0.00 (0.00%) as of 4:30 Tue 11/30
|
|
Download |
|
|
| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
80,420,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0 - $0 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Verve Therapeutics is a genetic medicines company developing an approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. Co.'s primary product candidate, VERVE-101, is designed to turn off the PCSK9 gene in the liver. PCSK9 is a validated target that plays a critical role in controlling blood low-density lipoprotein cholesterol through its regulation of the low-density lipoprotein receptor. Co.'s second program is designed to turn off the ANGPTL3 gene in the liver. ANGPTL3 is a main regulator of cholesterol and triglyceride metabolism.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
1,800,000 |
1,800,000 |
1,810,000 |
| Total Buy Value |
$0 |
$18,000,000 |
$18,000,000 |
$18,121,526 |
| Total People Bought |
0 |
1 |
1 |
2 |
| Total Buy Transactions |
0 |
1 |
1 |
2 |
| Total Shares Sold |
1,514 |
2,068 |
2,068 |
1,570,794 |
| Total Sell Value |
$12,475 |
$18,818 |
$18,818 |
$35,262,071 |
| Total People Sold |
1 |
2 |
2 |
7 |
| Total Sell Transactions |
1 |
2 |
2 |
35 |
| End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Casdin Private Growth Equity Fund, L.p. |
10% Owner |
– – • |
2021-06-21 |
4 |
A |
$0.00 |
$0 |
D/D |
620,571 |
620,571 |
|
- |
|
| Gv 2017, L.p. |
10% Owner |
– – • |
2021-06-21 |
4 |
A |
$0.00 |
$0 |
I/I |
6,320,905 |
6,320,905 |
|
- |
|
| Gv 2019, L.p. |
10% Owner |
– – • |
2021-06-21 |
4 |
A |
$0.00 |
$0 |
I/I |
4,472,509 |
4,472,509 |
|
- |
|
| Rock Springs Capital Llc |
10% Owner |
– – • |
2021-06-21 |
4 |
A |
$0.00 |
$0 |
I/I |
709,224 |
152,926 |
|
- |
|
| Rock Springs Capital Llc |
10% Owner |
– – • |
2021-06-21 |
4 |
B |
$19.00 |
$7,030,000 |
I/I |
370,000 |
926,298 |
1.5 |
- |
|
| Logos Global Management Lp |
10% Owner |
– – • |
2021-06-21 |
4 |
B |
$19.00 |
$7,030,000 |
D/D |
370,000 |
370,000 |
2.45 |
- |
|
| Logos Global Management Lp |
10% Owner |
– – • |
2021-06-21 |
4 |
A |
$0.00 |
$0 |
I/I |
443,265 |
443,265 |
|
- |
|
| Novo A/s |
10% Owner |
– – • |
2021-06-21 |
4 |
B |
$19.00 |
$6,650,000 |
D/D |
350,000 |
793,265 |
2.45 |
- |
|
| Novo A/s |
10% Owner |
– – • |
2021-06-21 |
4 |
A |
$0.00 |
$0 |
D/D |
443,265 |
443,265 |
|
- |
|
| Wellington Biomedical Innovation Master Investors |
10% Owner |
– – • |
2021-06-21 |
4 |
A |
$0.00 |
$0 |
D/D |
2,495,571 |
2,495,571 |
|
- |
|
| Yeshwant Krishna |
Director |
– • • |
2021-06-21 |
4 |
A |
$0.00 |
$0 |
I/I |
10,793,414 |
4,472,509 |
|
- |
|
| Casdin Partners Master Fund, L.p. |
10% Owner |
– – • |
2021-06-21 |
4 |
B |
$19.00 |
$20,900,000 |
D/D |
1,100,000 |
2,417,596 |
2.45 |
- |
|
| Casdin Partners Master Fund, L.p. |
10% Owner |
– – • |
2021-06-21 |
4 |
A |
$0.00 |
$0 |
D/D |
1,317,596 |
1,317,596 |
|
- |
|
| Green Jeremy |
10% Owner |
– – • |
2021-06-21 |
4 |
B |
$19.00 |
$19,950,000 |
I/I |
1,050,000 |
1,936,530 |
1.5 |
- |
|
| Green Jeremy |
10% Owner |
– – • |
2021-06-21 |
4 |
A |
$0.00 |
$0 |
I/I |
886,530 |
886,530 |
|
- |
|
| Cormorant Private Healthcare Fund Iii Lp |
Former 10% Owner |
– – – |
2021-06-21 |
4 |
B |
$19.00 |
$5,225,000 |
I/I |
275,000 |
984,224 |
0.01 |
- |
|
| Cormorant Private Healthcare Fund Iii Lp |
Former 10% Owner |
– – – |
2021-06-21 |
4 |
A |
$0.00 |
$0 |
I/I |
709,224 |
709,224 |
|
- |
|
| Fmr Corp |
See Remark 1 |
– – – |
2021-06-21 |
4 |
A |
$0.00 |
$0 |
I/I |
1,037,294 |
1,037,294 |
|
- |
|
| Gillis Steven |
10% Owner |
– – • |
2021-06-21 |
4 |
A |
$0.00 |
$0 |
I/I |
2,508,809 |
1,254,405 |
|
- |
|
| Broad Institute, Inc. |
10% Owner |
– – • |
2021-06-21 |
4 |
A |
$0.00 |
$0 |
D/D |
387,830 |
809,784 |
|
- |
|
| Beam Therapeutics Inc. |
10% Owner |
– – • |
2021-06-21 |
4 |
A |
$0.00 |
$0 |
D/D |
270,895 |
546,970 |
|
- |
|
| Beaudoin Margaret |
Vice President, Finance |
• – – |
2021-06-21 |
4 |
B |
$19.00 |
$19,000 |
D/D |
1,000 |
1,000 |
2.74 |
- |
|
| Kathiresan Sekar |
Chief Executive Officer |
• • – |
2021-06-21 |
4 |
B |
$19.00 |
$47,500 |
D/D |
2,500 |
406,536 |
2.81 |
- |
|
| Bellinger Andrew |
Chief Scientific Officer |
• – – |
2021-06-21 |
4 |
B |
$19.00 |
$95,000 |
D/D |
5,000 |
5,000 |
2.74 |
- |
|
99 Records found
|
|
Page 4 of 4 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
